The Phase 1 (ACTRN12625000212459p) randomized, double-blind, placebo-controlled, first-in-human study of single ascending doses of ABS-101 will evaluate safety, tolerability, pharmacokinetics (PK), ...

Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025 Ovid’s first program in its KCC2 direct activator library, OV350, ...

The poster can be accessed on Skye's Spotlight page .

The City of Geneva Police Department posted a ‘quick-fact’ sheet to its Facebook page over the weekend which included the ...

Greetings from 14 Grove St. We are gearing up to recognize our amazing volunteers on June 6 with a special luncheon sponsored by Settlers Green, here at the Gibson Center. It is impossible to put into ...

Advancing commercial readiness efforts with a planned Q1 2026 launch of Anaphylm, subject to FDA approval "In the first quarter of 2025, we achieved a major milestone for Aquestive with the submission ...

The following is a summary of “Model-informed identification of optimised dosing strategies for meropenem in critically ill ...

A body washed up at Its Beach in Santa Cruz Friday, almost a week after a swimmer disappeared beneath the waves after ...

First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer's Disease Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts ...

Pharmacokinetic (PK) model generated based on the single ascending dose (SAD) data and the first multiple ascending dose (MAD ...

The United States is pulling back from its role in spreading democratic ideals abroad under President Donald Trump. Experts ...

Q1 2025 Results Conference Call May 6, 2025 4:30 PM ETCompany ParticipantsBlake Beber - Head, IRSean Saint - President ...